Clinical Trial Update: Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update on surufatinib combined with toripalimab and chemotherapy for non-small cell lung cancer (NSCLC).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Surufatinib (Surufatinib)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Li Zhang, MD | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: UNKNOWN